These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2006-006886-18 Efficacy and Safety of Vivitrol® in Adults Completing Inpatient Treatment for Alcohol Dependence 2011-01-04 due-trials
Reported results 2012-003445-15 A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of ALKS 9072 in Subjects with Acute Exacerbation of Schizophrenia 2014-03-11 due-trials
Reported results 2012-003996-20 A Phase 3, Multicenter, Extension of Study ALK9072-003 to Assess the Long-term Safety and Durability of Effect of ALKS 9072 in Subjects with Stable Schizophrenia 2015-04-28 due-trials
Reported results 2013-002193-45 A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALK 3831, in Adults with Schizophrenia Treated with Olanzapine Randomizovaná, multice... 2015-03-09 due-trials
Reported results 2014-000379-14 A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-5 Study) 2016-09-27 due-trials
Reported results 2014-000380-41 A Phase 3 Multicenter Study of the Long-term Safety and Tolerability of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder in Adults who Have an Inadequate Response to Antidepressant ... 2017-11-20 due-trials
Reported results 2014-000399-25 A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study) 2015-12-23 due-trials
Reported results 2014-001211-39 A Phase 2, Efficacy, Safety, and Tolerability Study of ALKS 3831 in Schizophrenia with Alcohol Use Disorder 2017-02-01 due-trials
Reported results 2015-003373-15 A Phase 3 Study to Determine the Antipsychotic Efficacy and Safety of ALKS 3831 in Adult Subjects with Acute Exacerbation of Schizophrenia 2017-06-07 due-trials
Reported results 2015-003880-13 A Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects with Schizophrenia 2018-06-18 due-trials
Completed, report not yet due 2015-005160-41 A Phase 3 Open Label Study to Evaluate the Long-term Safety and Tolerability of ALKS 8700 in Adults with Relapsing Remitting Multiple Sclerosis 2021-11-11 not-yet-due
Listed as ongoing, but also has a completion date 2017-000497-11 A Study to Evaluate the Effect of ALKS 3831 Compared to Olanzapine on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness 2021-12-01 bad-data
Ongoing 2017-000918-36 A Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subjects with Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder not-yet-due
Reported results 2017-001294-16 A Phase 3 Study in Subjects with Relapsing Remitting Multiple Sclerosis to Evaluate the Tolerability of ALKS 8700 and Dimethyl Fumarate 2019-06-27 due-trials
Exempt 2019-001998-90 A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors- ARTISTRY-1 not-yet-due
Exempt 2019-002013-20 A Phase 1/2 Study of ALKS 4230 Administered Subcutaneously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (ARTISTRY-2) 2021-02-23 not-yet-due
Ongoing 2021-001557-31 A Phase 2, Open-label, Multicenter, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy Administered Subcutaneously in Patients With Advanced Cutaneous Melanoma or Intravenously in Patients With ... not-yet-due
Ongoing 2021-002326-24 A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator’s Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovar... not-yet-due